Although leptin receptor antagonist therapies are still undergoing clinical trials, leptin is still considered a candidate cancer treatment due to its unique status as a link between obesity and cancer [23, 24]. The gene discussed is LEPR; the disease is obesity due to melanocortin 4 receptor deficiency.